CJC-1295 No DAC: Mechanism of Action in Research Models

The CJC-1295 No DAC mechanism of action is studied through the GHRH receptor on pituitary somatotroph cells. Somatotrophs are the cells that release growth hormone. CJC-1295 No DAC is also called modified GRF (1-29). It is a synthetic, 29-amino-acid analog of growth hormone-releasing hormone (GHRH). It carries stabilizing swaps but leaves out the Drug Affinity Complex (DAC). The notes below come from biochemical assays, cell cultures, and animal models. Read them strictly in a research context.

What is the CJC-1295 No DAC mechanism of action?

CJC-1295 No DAC acts as a GHRH-receptor agonist, meaning it turns the receptor on. It is modeled on GHRH (1-29), the active fragment of the native hormone. Labs use it as a model for the somatotropic axis, the hormone chain that controls growth hormone release.

Its value as a tool is a rare mix of traits. It resists enzyme breakdown better than native GHRH. Yet it still acts for only a short time, because it lacks the albumin-binding group of the DAC form. The native peptide cannot offer this mix. That is why the modified analog became a standard tool for timed receptor studies.

The compound is well defined chemically:

• Formula: C152H252N44O42
• CAS number: 863288-34-0
• Molecular weight: about 3367.9 g/mol

These confirmed values let labs standardize concentration and molar math. A stimulus described in one lab can then be copied faithfully in another.

How does CJC-1295 No DAC engage the GHRH receptor?

In test systems, GHRH receptor activation is linked to cAMP-dependent signaling in somatotroph cells. It also starts the pulsed release of growth hormone. CJC-1295 No DAC is studied as a typical GHRH (1-29) analog. It gives labs a defined stimulus to probe the receptor and the chain of events that follows.

The receptor is a class B G-protein-coupled receptor. It signals through the cAMP/PKA axis. This is the standard entry point for the somatotroph signaling these studies describe.

Native GHRH and related analogs such as sermorelin use this same pathway. So the compound is used to build receptor data sets that compare directly. The analog is chemically defined and more stable. It gives a cleaner, more repeatable stimulus than the native peptide. That removes one source of noise in mechanism work.

Why is CJC-1295 No DAC stable but short-acting?

The swaps that set modified GRF (1-29) apart from native GHRH are studied for one key role. They make the peptide less prone to cutting by an enzyme called dipeptidyl peptidase. This extends its in-vitro stability compared with the native peptide.

This form has no albumin-binding DAC group. So it lasts only a short time in circulation compared with the DAC form. The result is a molecule that resists fast breakdown but does not linger. That is just the profile needed to model brief signaling events.

• A GRF (1-29) backbone with four swaps, studied for resistance to dipeptidyl peptidase
• No Drug Affinity Complex, so no albumin binding and no extended half-life
• Short, timed receptor activation suited to pulsed-signaling studies

The short action is a chosen research feature, not a flaw. It lets labs model receptor signaling over time. A long-acting analog keeps the receptor occupied. The No-DAC form lets a stimulus be applied, watched, and cleared. That is essential for studying recovery speed and repeated-pulse behavior.

How does CJC-1295 No DAC compare with the DAC form?

The No-DAC form is often studied next to its long-acting partner. This contrasts pulsed and sustained GHRH receptor activation within one framework. The sustained profile is covered in the CJC-1295 With DAC mechanism of action.

Comparing the two shows how albumin binding reshapes signal duration. Running both forms in the same model makes duration the test variable. The receptor stays the same.

This paired design is one of the clearest ways to study timing. It shows how the time course of a stimulus, not its identity, shapes downstream signaling. It turns a drug-like difference into a controlled variable. The design recurs often in somatotropic-axis research.

How does CJC-1295 No DAC work with GHS-receptor agonists?

CJC-1295 No DAC acts on the GHRH receptor. Ghrelin and GHS agonists act on a separate receptor. So the two are often paired in studies of converging signals.

The GHS side uses a phospholipase-C-coupled pathway. It is described in the Ipamorelin mechanism of action. This two-pathway logic is the basis of the combined blend. It is explored further in the CJC-1295 No DAC research applications.

Both receptors act on the same somatotroph cells. But they use different second-messenger systems. That makes the pair a natural subject for studies of signal integration. Testing the GHRH arm alone with the No-DAC analog comes first. Only then can a combined effect be credited to convergence, not to either pathway by itself.

What makes the modified backbone resist enzymes?

The stabilizing swaps in modified GRF (1-29) explain why the analog behaves differently from native GHRH at the bench. Dipeptidyl peptidase cuts native GHRH quickly. Its working concentration falls fast and unpredictably. That limits its use as a defined stimulus.

The four-swap backbone is studied for its resistance to this cut. It gives the analog a steadier presence in vitro. It does so without adding albumin binding, which would push it into the sustained range.

This middle profile is what makes the No-DAC form useful for pulsed-signaling work. It is more stable than native GHRH, yet still short-acting. It gives a repeatable stimulus that starts and ends within a set window. Neither the fragile native peptide nor the long-acting DAC form can do this.

How should CJC-1295 No DAC mechanism data be read?

Current knowledge comes from in-vitro assays, animal models, and human research on related GHRH analogs. Treat each finding as a result within its test setting. Do not read findings as established clinical outcomes.

The strength of the No-DAC form as a tool is its defined chemistry and short action. These make its stimulus repeatable. Still, each conclusion belongs to the model that produced it. Stable, well-tested material is what lets the short signal be read cleanly.

Labs can review mixing practice in the CJC-1295 No DAC handling guide. Material with a certificate of analysis is available on the CJC-1295 No DAC product page.

For research use only. CJC-1295 No DAC is an investigational research peptide and is not approved for human or veterinary use. All descriptions refer to preclinical and in vitro laboratory research.